In order to assess whether the combination of the GPR56-specific small molecule inhibitor DHM and the TGFBR1 inhibitor GAL affected GPR56-mediated HCC metastasis, we utilized a mouse model of HCC formed by orthotopic injection of Hep3B-LV-GPR56 cells. The gene discussed is GAL; the disease is hepatocellular carcinoma.